I'm LongbridgeAI, I can summarize articles.The Week
Legend Biotech (LEGN) gained 8.18% this week to close at $23.40, while the S&P 500 fell 2.68%, leaving the stock roughly 10.86 percentage points ahead of the benchmark. The week started with a dip to $20.99 on Monday, followed by four straight days of recovery. Volume picked up on Wednesday, and the stock hit a weekly high of $23.98 on Thursday before settling at $23.40 on Friday. The week’s amplitude was 13.73%, with average daily volume about 12.6% above the 5-day median.
Key Events
The main story this week was LB2501 clinical data and the ASH annual meeting schedule. After the close on 4 November, Legend disclosed that LB2501 showed a 100% complete response rate in eight patients at dose level 2; the stock climbed more than 6% intraday the next day. The company and parent GenScript followed with announcements that Legend will present cell-therapy data at the American Society of Hematology (ASH) 2026 annual meeting, including CAR-T research findings on multiple myeloma. On 6 November, attention turned to how ASH abstract acceptances might affect the stock. There were no material filings or non-routine disclosures this week.
Analyst Ratings
Among the 13 institutions covering Legend Biotech, 5 rate it buy, 5 rate it outperform, and 3 rate it hold, with no sell or underperform ratings. The consensus recommendation is buy, with a consensus target price of $45.62, about 95.0% above the current price. Target prices range from $24.00 to $68.00, showing wide dispersion. Within the biotech industry, Legend ranks 98th out of 510 companies in terms of rating coverage, while the industry median is 6 institutions.
The Week Ahead
Legend Biotech reports Q3 FY2026 results on Tuesday, 10 November, with consensus estimates at $0.0118 EPS on $360 million in revenue. The same day brings US CPI and core CPI data, with core CPI at 2.6 prior and 2.8 forecast, which may shift risk appetite. On Monday, 9 November, US wholesale sales data are due. The company’s FY2026 annual results are scheduled for 10 March 2027.
In Short
The stock’s gains this week coincided with the LB2501 complete response data and ASH presentation schedule, while the analyst setup remains broadly positive with a consensus target well above spot. The latest trading day showed large-lot money as a net buyer, but medium and small flows diverged, and the company remains loss-making on a valuation basis. The near-term focus is on Q3 results and further ASH abstract momentum, alongside how CPI data shapes overall risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.